Sulfateq BV | Empowering health
  • Home
  • About us
  • Programs & Pipeline
  • Scientific data
  • Partnering
    • Investors
  • Newsroom
  • Contact us
Select Page

Dagblad van het Noorden ‘Een nieuw molecuul uit Groningen als wapen tegen oude ziektes’

by Raymond Tel | Feb 28, 2024 | News

SUL-238: A Groundbreaking First-in-Class Medication Targeting Mitochondrial Dysfunction in Multiple Chronic Diseases

by Raymond Tel | Feb 24, 2024 | News

This week, the first dosings of SUL-238 in healthy volunteers in a Phase I study marks a major milestone in the clinical development of this hibernation-derived, first-in-class drug. The phase I study investigates the safety, tolerability and pharmacokinetics after...

Major breakthrough in potential new treatment for Sepsis with Sulfateq’s lead compound SUL-138

by Raymond Tel | Apr 7, 2023 | News

Great news! A new scientific paper has been published about the potential of a new medicine, SUL-138, to help treat sepsis. Sepsis is a serious health problem, but right now doctors can only use antibiotics and supportive care to help patients. SUL-138 targets the...

Sulfateq is proud to announce the results of a new study which might provide a new way to treat  Alzheimer’s disease.

by Raymond Tel | Dec 14, 2022 | News

Alzheimer’s Disease (AD) is a complex and progressive neurodegenerative disease which is characterized by memory loss and cognitive impairment. It is one of the most prevalent neurodegenerative diseases and it is estimated that the number of patients will increase...

Sulfateq is in the finals of the LIFE Science Innovation Award!

by Raymond Tel | Aug 1, 2022 | News

We at Sulfateq are very proud to have reached the finals out of more than twenty applications. The Innovation Award is awarded to the innovation with the most impact in the field of Life Sciences & Health. During the final on September 27, we will pitch our...
« Older Entries
Next Entries »
  • RSS
Sulfateq BV - Copyright 2021